Costs of second allogeneic hematopoietic cell transplantation

Nandita D Khera, Barry Storer, Brenda M. Sandmaier, Michael K. Chapko, Stephanie J. Lee

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

BACKGROUND: A second allogeneic transplantation after a prior allogeneic (allo-allo) or autologous (auto-allo) hematopoietic cell transplantation (HCT) is usually performed for graft failure, disease recurrence, secondary malignancy, and, as planned, auto-allo transplantation for some diseases. METHODS: We sought to describe the costs of second allogeneic HCT and evaluate their relationship with patient characteristics and posttransplantation complications. Clinical information and medical costs for the first 100 days after transplantation of 245 patients (allo-allo, 55; auto-allo, 190) who underwent a second HCT between 2004 and 2010 were collected. RESULTS: Median costs of the second allogeneic HCT were U.S. $151,000 (range, U.S. $62,000-405,000) for the allo-allo group and U.S. $109,000 (range, U.S. $26,000-490,000) for the auto-allo group. Median length of hospital stay was 23 days (range, 0-76) for the allo-allo group and 9 days (range, 0-96) for the auto-allo group. Only the year of transplantation and posttransplantation complications were significantly associated with costs in both groups when both pre- and posttransplantation variables were considered. The overall costs of the second HCT were higher than the first in the allo-allo group. For the auto-allo group, there was no difference between the costs whether preformed as a planned tandem or as salvage for relapse. CONCLUSIONS: Our results suggest that second allogeneic HCT is costly, particularly if it follows a prior allogeneic transplantation, and is driven by the costs of complications.

Original languageEnglish (US)
Pages (from-to)108-115
Number of pages8
JournalTransplantation
Volume96
Issue number1
DOIs
StatePublished - Jul 15 2013

Fingerprint

Cell Transplantation
Costs and Cost Analysis
Transplantation
Homologous Transplantation
Length of Stay
Recurrence
Transplants
Neoplasms

Keywords

  • Cost effectiveness
  • Costs
  • Economics
  • Hematopoietic cell transplantation
  • Pharmacoeconomics

ASJC Scopus subject areas

  • Transplantation

Cite this

Khera, N. D., Storer, B., Sandmaier, B. M., Chapko, M. K., & Lee, S. J. (2013). Costs of second allogeneic hematopoietic cell transplantation. Transplantation, 96(1), 108-115. https://doi.org/10.1097/TP.0b013e318294caf1

Costs of second allogeneic hematopoietic cell transplantation. / Khera, Nandita D; Storer, Barry; Sandmaier, Brenda M.; Chapko, Michael K.; Lee, Stephanie J.

In: Transplantation, Vol. 96, No. 1, 15.07.2013, p. 108-115.

Research output: Contribution to journalArticle

Khera, ND, Storer, B, Sandmaier, BM, Chapko, MK & Lee, SJ 2013, 'Costs of second allogeneic hematopoietic cell transplantation', Transplantation, vol. 96, no. 1, pp. 108-115. https://doi.org/10.1097/TP.0b013e318294caf1
Khera, Nandita D ; Storer, Barry ; Sandmaier, Brenda M. ; Chapko, Michael K. ; Lee, Stephanie J. / Costs of second allogeneic hematopoietic cell transplantation. In: Transplantation. 2013 ; Vol. 96, No. 1. pp. 108-115.
@article{2b640d017c5644e48729077462a34586,
title = "Costs of second allogeneic hematopoietic cell transplantation",
abstract = "BACKGROUND: A second allogeneic transplantation after a prior allogeneic (allo-allo) or autologous (auto-allo) hematopoietic cell transplantation (HCT) is usually performed for graft failure, disease recurrence, secondary malignancy, and, as planned, auto-allo transplantation for some diseases. METHODS: We sought to describe the costs of second allogeneic HCT and evaluate their relationship with patient characteristics and posttransplantation complications. Clinical information and medical costs for the first 100 days after transplantation of 245 patients (allo-allo, 55; auto-allo, 190) who underwent a second HCT between 2004 and 2010 were collected. RESULTS: Median costs of the second allogeneic HCT were U.S. $151,000 (range, U.S. $62,000-405,000) for the allo-allo group and U.S. $109,000 (range, U.S. $26,000-490,000) for the auto-allo group. Median length of hospital stay was 23 days (range, 0-76) for the allo-allo group and 9 days (range, 0-96) for the auto-allo group. Only the year of transplantation and posttransplantation complications were significantly associated with costs in both groups when both pre- and posttransplantation variables were considered. The overall costs of the second HCT were higher than the first in the allo-allo group. For the auto-allo group, there was no difference between the costs whether preformed as a planned tandem or as salvage for relapse. CONCLUSIONS: Our results suggest that second allogeneic HCT is costly, particularly if it follows a prior allogeneic transplantation, and is driven by the costs of complications.",
keywords = "Cost effectiveness, Costs, Economics, Hematopoietic cell transplantation, Pharmacoeconomics",
author = "Khera, {Nandita D} and Barry Storer and Sandmaier, {Brenda M.} and Chapko, {Michael K.} and Lee, {Stephanie J.}",
year = "2013",
month = "7",
day = "15",
doi = "10.1097/TP.0b013e318294caf1",
language = "English (US)",
volume = "96",
pages = "108--115",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Costs of second allogeneic hematopoietic cell transplantation

AU - Khera, Nandita D

AU - Storer, Barry

AU - Sandmaier, Brenda M.

AU - Chapko, Michael K.

AU - Lee, Stephanie J.

PY - 2013/7/15

Y1 - 2013/7/15

N2 - BACKGROUND: A second allogeneic transplantation after a prior allogeneic (allo-allo) or autologous (auto-allo) hematopoietic cell transplantation (HCT) is usually performed for graft failure, disease recurrence, secondary malignancy, and, as planned, auto-allo transplantation for some diseases. METHODS: We sought to describe the costs of second allogeneic HCT and evaluate their relationship with patient characteristics and posttransplantation complications. Clinical information and medical costs for the first 100 days after transplantation of 245 patients (allo-allo, 55; auto-allo, 190) who underwent a second HCT between 2004 and 2010 were collected. RESULTS: Median costs of the second allogeneic HCT were U.S. $151,000 (range, U.S. $62,000-405,000) for the allo-allo group and U.S. $109,000 (range, U.S. $26,000-490,000) for the auto-allo group. Median length of hospital stay was 23 days (range, 0-76) for the allo-allo group and 9 days (range, 0-96) for the auto-allo group. Only the year of transplantation and posttransplantation complications were significantly associated with costs in both groups when both pre- and posttransplantation variables were considered. The overall costs of the second HCT were higher than the first in the allo-allo group. For the auto-allo group, there was no difference between the costs whether preformed as a planned tandem or as salvage for relapse. CONCLUSIONS: Our results suggest that second allogeneic HCT is costly, particularly if it follows a prior allogeneic transplantation, and is driven by the costs of complications.

AB - BACKGROUND: A second allogeneic transplantation after a prior allogeneic (allo-allo) or autologous (auto-allo) hematopoietic cell transplantation (HCT) is usually performed for graft failure, disease recurrence, secondary malignancy, and, as planned, auto-allo transplantation for some diseases. METHODS: We sought to describe the costs of second allogeneic HCT and evaluate their relationship with patient characteristics and posttransplantation complications. Clinical information and medical costs for the first 100 days after transplantation of 245 patients (allo-allo, 55; auto-allo, 190) who underwent a second HCT between 2004 and 2010 were collected. RESULTS: Median costs of the second allogeneic HCT were U.S. $151,000 (range, U.S. $62,000-405,000) for the allo-allo group and U.S. $109,000 (range, U.S. $26,000-490,000) for the auto-allo group. Median length of hospital stay was 23 days (range, 0-76) for the allo-allo group and 9 days (range, 0-96) for the auto-allo group. Only the year of transplantation and posttransplantation complications were significantly associated with costs in both groups when both pre- and posttransplantation variables were considered. The overall costs of the second HCT were higher than the first in the allo-allo group. For the auto-allo group, there was no difference between the costs whether preformed as a planned tandem or as salvage for relapse. CONCLUSIONS: Our results suggest that second allogeneic HCT is costly, particularly if it follows a prior allogeneic transplantation, and is driven by the costs of complications.

KW - Cost effectiveness

KW - Costs

KW - Economics

KW - Hematopoietic cell transplantation

KW - Pharmacoeconomics

UR - http://www.scopus.com/inward/record.url?scp=84879839786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879839786&partnerID=8YFLogxK

U2 - 10.1097/TP.0b013e318294caf1

DO - 10.1097/TP.0b013e318294caf1

M3 - Article

C2 - 23694949

AN - SCOPUS:84879839786

VL - 96

SP - 108

EP - 115

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 1

ER -